Cytosorbents Corp Files 8-K
Ticker: CTSO · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1175151
| Field | Detail |
|---|---|
| Company | Cytosorbents CORP (CTSO) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financial-statements
TL;DR
CYTOSORBENTS CORP FILED STANDARD 8-K - NO NEW NEWS.
AI Summary
Cytosorbents Corporation filed an 8-K on December 23, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a standard disclosure for Cytosorbents Corporation, indicating updates related to financial statements and exhibits, without revealing new material information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any new risks or material changes.
Key Players & Entities
- Cytosorbents Corporation (company) — Registrant
- MedaSorb Technologies CORP (company) — Former company name
- GILDER ENTERPRISES INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing for Cytosorbents Corporation?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on December 23, 2024.
What is the principal executive office address for Cytosorbents Corporation?
The principal executive office address is 305 College Road East, Princeton, New Jersey 08540.
What is Cytosorbents Corporation's state of incorporation?
Cytosorbents Corporation is incorporated in Delaware.
Does this filing indicate any new material events or financial results?
Based on the provided text, this filing appears to be a standard disclosure for financial statements and exhibits, and does not explicitly mention new material events or specific financial results.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-12-23 16:05:10
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value CTSO The Nasdaq Stock Marke
Filing Documents
- tm2431903d1_8k.htm (8-K) — 26KB
- tm2431903d1_ex99-1.htm (EX-99.1) — 21KB
- tm2431903d1_ex99-1img001.jpg (GRAPHIC) — 34KB
- 0001104659-24-131274.txt ( ) — 270KB
- ctso-20241223.xsd (EX-101.SCH) — 3KB
- ctso-20241223_lab.xml (EX-101.LAB) — 33KB
- ctso-20241223_pre.xml (EX-101.PRE) — 22KB
- tm2431903d1_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure On December 23, 2024, CytoSorbents Corporation (the "Company") issued a press release announcing the commencement of its previously announced rights offering. A copy of the press release is furnished herewith as Exhibit 99.1.*
01
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated December 23, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) *The information in this Item 7.01 of this Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 23, 2024 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer